Melatonin involvement in immunity and cancer

NeuroSignals

Volumn 7, Issue 1, 1998, Pages 61-72

  Fraschini, F ^a   Demartini, G ^a   Esposti, D ^b   Scaglione, F ^a  

^a Department of Pharmacology ^*  (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Extrapineal synthesis; Immune system; Melatonin; Neoplastic growth; Photoperiod; Seasonality

Indexed keywords

INTERLEUKIN 2; MELATONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CONTROLLED STUDY; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE SYSTEM; NONHUMAN; PHOTOPERIODICITY; PINEAL BODY; RAT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNITY; MELATONIN; NEOPLASMS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0031802340     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000014529     Document Type: Article

References (131)

1. Blalock JE: A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 1989;69: 1-32.
2. Blask D, Pelletier D, Hill S, Lemus-Wilson A, Grosso D, Wilson S, Wise M: Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methyl-urea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 1991;117:526-532.
3. Ader R, Felten DL, Cohen N (eds): Psychoneuroimmunology II. San Diego, Academic Press, 1991.
4. Maestroni GJ, Conti A, Pierpaoli W: Role of the pineal gland in immunity: Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 1986; 13:19-30.
5. Huether G, Poeggeler B, Reimer A, George A: Effect of tryptophan administration on circulating melatonin levels in chicks and rats: Evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992;51:945-953.
6. Launay JM, Lamaitre BJ, Husson HP, Dreux C, Hartmenn L, Da Prada M: Melatonin synthesis by rabbit platelets. Life Sci 1982;31: 1487-1494.
7. Finocchiaro LM, Artz ES, Fernan-dez-Castelo S, Criscuolo M, Finkiel-man S, Nahmod VE: Serotonin and melatonin synthesis in peripheral blood mononuclear cells, stimulation by interferon gamma as part of an immunomodulatory pathway. J Interferon Res 1988;8:705-716.
8. Finocchiaro LM, Nahmod VE, Launay JM: Melatonin biosynthesis and metabolism in peripheral blood mononuclear leukocytes. Biochem J 1991;280:727-731.
9. Finocchiaro LM, Polack E, Nahmod VE, Glikin GC: Sensitivity of human peripheral blood mononuclear leukocytes to visible light. Life Sci 1995;57:1097-1110.
10. Reiter RJ: Melatonin: The chemical expression of darkness. Mol Cell Endocrinol 1991;79:C153-C158.
11. Bartness TJ, Goldman BD: Mammalian pineal melatonin: A clock for all seasons. Experientia 1989;45: 939-945.
12. Waldhauser F, Weiszenbacher G, Tatzer E, Gisinger B, Waldhauser M, Schemper M, Frisch H: Alteration in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988;66:648-652.
13. Moore-Ede MC, Sulzman FNM, Fuller CA (eds): The Clock That Time Us. Cambridge, Harvard University Press, 1982.
14. Carandente F, Angeli A, De Vecchi, Dammacco F, Halberg F: Multifrequency rhythms of immunological functions. Chronobiologia 1988; 15: 7-23.
15. Nakano Y, Hara I, Miura T, Aono H, Miyano N, Miyajima K, Tabuchi T, Kosawa H: The effect of shift work on cellular immune function. J Hum Ergol 1982; 11(suppl): 131-137.
16. Ohkoshi H, Asukata I, Tajima N, Yamamoto K, Sasaki M, Hokari M, Sakai T: The influence of transmeridian flight on human circulating lymphocytes. Aviat Space Environ Med 1991;62:14-18.
17. Nelson RJ, Demas GE, Klein SL, Kriegsfeld LJ: The influence of season, photoperiod, and pineal melatonin on immune function. J Pineal Res 1995;19:149-165.
18. Liebmann PM, Wolfler A, Felsner P, Hofer D, Schauenstein K: Melatonin and immune system. Arch Allergy Immunol 1997;112:203-211.
19. Csaba G, Bodoky M, Toro I: Hormonal relationship of mastocyto-genesis in lymphatic organs. II. Effect of epiphysectomy on the genesis of mast cells. Acta Anat (Basel) 1965;61:289-296.
20. Csaba G, Barath P: Morphological changes of thymus and the thyroid gland after postnatal extirpation of pineal body. Endocrinol Exp 1975; 9:59-67.
21. Jankovic D, Isakovic K, Petrovic S: Effects of pinealectomy on immune reaction in the rat. Immunol 1970; 18:1-6.
22. Maestroni GJ, Pierpaoli W: Pharmacologic control of the hormonally mediated immune response; in Ader R (ed): Psychoneuroimmunology. London, Academic Press, 1981, pp 405-413.
23. Maestroni GJ, Conti A, Pierpaoli W: Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 1986; 13:19-30.
24. Franco P, Scaglione F, Marelli O, Ricci L, Ferrara F, Fraschini F: Preliminary results regarding a possible immunomodulatory effect of melatonin in B16 tumor bearing mice. Proc 16th Int Congr Chemother, Jerusalem, 1989, pp 897.1-897.2.
25. Garza HH Jr, Stankov B, Fraschini F, Carr DJJ: The relationship between opioids and melatonin in the immune system. Neuroendocrinol Lett 1993;15:135-148.
26. Maestroni GJ, Conti A, Pierpaoli W: Role of the pineal gland in immunity. III. Melatonin antagonizes the immunosuppressive effect of acute stress via an opiatergic mechanism. Immunology 1988;63:465-469.
27. Maestroni GJ, Conti A, Pierpaoli W: Role of the pineal gland in immunity. II. Melatonin enhances the antibody response via an opiatergic mechanism. Clin Exp Immunol 1987;68:384-391.
28. Maestroni GJ, Conti A: P-Endor-phin and dynorphin mimic the circadian immunoenhancing and antistress effect of melatonin. Int J Im-munopharmacol 1989;11:333-340.
29. Maestroni GJ, Conti A: The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with im-munoenhancing and anti-stress properties. J Neuroimmunol 1990; 28:167-176.
30. Maestroni GJ, Conti A: Anti-stress role of the melatonin-opioid-network: Evidence for a physiological mechanism involving T cell derived, immunoreactive P-endorphin and Met-enkephalin binding to thymic opioid receptors. Int J Neurosci 1991;61:289-298.
31. Wajs E, Kutoh E, Gupta D: Melatonin affects proopiomelanocortin gene expression in the immune organs of the rat. Eur J Endocrinol 1995;133:754-760.
32. Ovadia H, Nitsan P, Abramsky O: Characterization of opiate binding sites on membranes of rat lymphocytes. J Neuroimmunol 1989;21: 93-102.
33. Bidlack JM, Lawrence DMP, Igna-towski TA: Kappa opioid receptors on immune cells as studied by fluorescent ligands. Adv Exp Med Biol 1996;402:13-22.
34. Del Gobbo V, Libri V, Villani R, Calib G, Nistico G: Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int J Immunopharmacol 1989; 11: 567-577.
35. Caroleo MC, Frasca D, Nistico G, Doria G: Melatonin as immunomo-dulator in immunodeficient mice. Immunopharmacology 1992;23:81-89.
36. Pioli C, Caroleo MC, Nistico G, Doria G: Melatonin increases antigen presentation and amplified specific and non specific signals for T-cell proliferation. Int J Immunopharma-col 1993;15:463-469.
37. Morrey MK, McLachlan JA, Serkin CD, Bakouche O: Activation of human monocytes by the pineal hormone melatonin. J Immunol 1994; 153:2671-2680.
38. Finocchiaro LE, Nahmod E, Launay JM: Melatonin biosynthesis and metabolism in peripheral blood mononuclear leukocytes. Biochem J 1991; 280:727-732.
39. Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maes-troni GJ: Immunological effects of a single evening subcutaneous injection of low dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J Biol Regul Homeost Agents 1992;6:132-136.
40. Lissoni P, Barni S, Cattaneo G, Archili C, Rovelli F, Rescaldani R, Brivio F, Pelizzoni F, Esposti D, Demartini G, Scaglione F, Fraschini F: Pineal-interleukin-2 interactions and their possible importance in the pathogenesis of immune dysfunctions in cancer; in Fraschini F, Reiter RJ, Stankov B (eds): Role of Melatonin and Pineal Peptides in Neu-roimmunomodulation. NATO ASI Series, Life Sci. New York, Plenum, 1991, vol 204, pp 273-280.
41. Maestroni GJ, Conti A, Lissoni P: Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 1994;54:4740-4743.
42. Maestroni GJ, Covacci V, Conti A: Hematopoietic rescue via T-cell-de-pendent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor bearing mice. Cancer Res 1994;54:2429-2432.
43. Maestroni JM, Hertens E, Galli P: New T helper cell opioid cytokines as mediators of the immunological and hematopoietic action of melatonin; in Maestroni GJ, Conti A, Reiter RJ (eds): Therapeutic Potential of Melatonin. Front Horm Res. Basel, Karger, 1997, vol 23, pp 6271.
44. Felsner P, Hofer D, Rinner I, Mangge H, Griber M, Korsatko W, Schauenstein K: Continuous in vivo treatment with catecholamines suppresses in vitro reactivity of rat peripheral blood T lymphocytes via • mediated mechanisms. J Neuroim-munol 1992;37:47-57.
45. McLeod SD, Cairncross KD: Preliminary evidence of a synergistic a1- and p1-adrenoceptor regulation of rat pineal hydroxyindole-O-meth-yltransferase. Gen Comp Endocrinol 1995;97:283-288.
46. Felsner P, Hofer D, Rinner I, Porta S, Korsatko W, Schauenstein K: Adrenergic suppression of peripheral blood T cell reactivity in the rat is due to activation of peripheral a2 receptors. J Neuroimmunol 1995; 57:27-34.
47. Liebmann PM, Hofer D, Felsner P, Wolfler A, Schauenstein K: Beta blockade enhances adrenergic immunosuppression in rats via inhibition of melatonin release. J Neu-roimmunol 1996;67:137-142.
48. Giordano M, Palermo MS: Melatonin-induced enhancement of anti-body-dependent cellular cytotoxicity. J Pineal Res 1991;10:117-121.
49. Giordano M, Vermeulen M, Palermo MS: Seasonal variation in antibody-dependent cellular cytotoxicity regulation by melatonin. FASEB J 1993;7:1052-1054.
50. Konakchieva R, Kyurkchiev S, Ke-hayov I, Taushanova P, Kanchev L: Selective effect of methoxyindoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J Neuroimmu-nol 1995;63:125-132.
51. Vijayalaxmi, Reiter RJ, Leal BZ, Meltz ML: Effect of melatonin on mitotic and proliferation indices, and sister chromatid exchange in human blood lymphocytes. Mutat Res 1996;351:187-192.
52. Artz ES, Fernandez-Castelo S, Fi-nocchiaro LM, Criscuolo Me, Diaz A, Finkielman S, Nahmod VE: Im-munomodulation by indoleamines: Serotonin and melatonin action on DNA and interferon-gamma synthesis by human peripheral blood mononuclear cells. J Clin Immunol 1988;8:513-520.
53. Di Stefano A, Paulesu L: Inhibitory effect of melatonin on production of IFN gamma or TNF alpha in peripheral blood mononuclear cells of some blood donors. J Pineal Res 1994;17:164-169.
54. Guerrero JM, Reiter RJ: A brief survey of pineal gland-immune system interrelationship. Endocr Res 1992; 18:91-113.
55. Calvo JR, Rafii-el-Idrissi M, Pozo D, Guerrero JM: Immunomodulatory role of melatonin: Specific binding sites in human and rodent lymphoid cells. J Pineal Res 1995; 18:119-126.
56. Lopez-Gonzales MA, Calvo JR, Osuna C, Guerrero JM: Interaction of melatonin with human lymphocytes: Evidence for binding sites coupled to potentiation of cyclic AMP stimulated by vasoactive intestinal peptide and activation of cyclic GMP. J Pineal Res 1992; 12:97104.
57. Lopez-Gonzales MA, Calvo JR, Osuna C, Rubio A, Guerrero JM: Synergistic action of melatonin and vasoactive intestinal peptide in stimulating cyclic AMP production in human lymphocytes. J Pineal Res 1992;12:174-180.
58. Lopez-Gonzales MA, Calvo JR, Segura JJ, Guerrero JM: Characterization of melatonin binding sites in human peripheral blood neutrophils. Biotechnol Ther 1993;4:253-262.
59. Gonzales-Haba MG, Garcia-Mauri-no S, Calvo JR, Goberna R, Guerrero JM: High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J 1995;9: 1331-1335.
60. 125I]iodomelato-nin by rat splenocytes: Characterization and its role on regulation of cyclic AMP production. J Neuroim-munol 1995;57:171-178.
61. 125I]melatonin by rat thymus membranes during postnatal development. Immunol Lett 1993;36:59-64.
62. 125I]melatonin by rat spleen crude membranes: Day/night variations and effect of pinealecto-my and continuous light exposure. J Pineal Res 1996;20:33-38.
63. Morgan PJ, Lawson W, Davidson G, Howell HE: Melatonin inhibits cyclic AMP production in cultured ovine pars tuberalis cells. J Mol Endocrinol 1989;3:R5-R8.
64. Stankov B, Fraschini F, Reiter RJ: Melatonin binding sites in the central nervous system. Brain Res Rev 1991;16:245-256.
65. Guerrero JM, Rafii-El-Idrissi M, Garcia-Perganeda A, Garcia-Mauri-no S, Gil-Haba M, Pozo D, Calvo JR: Mechanism of action of melatonin on the human immune system, in Maestroni GJM, Conti A, Reiter RJ (eds): Therapeutic Potential of Melatonin. Front Horm Res. Basel, Karger, 1997, vol 23, pp 4351.
66. Carlson LL, Weaver DR, Reppert SM: Melatonin signal transduction in hamster brain: Inhibition of adenyl cyclase by a pertussis toxin-sensitive G protein. Endocrinology 1989;125:2670-2676.
67. Laitinen JT, Flügge G, Saavedra JM: Characterization of melatonin receptors in the rat area postrema: Modulation of affinity with cations and guanine nucleotides. Neuroendocrinology 1990;51:619-624.
68. Pozo D, Delgado M, Calvo JR, Gar-cia-Pergañeda A, Guerrero JM: Expression of the membrane melatonin receptor mRNA in rat thymus and spleen; in Maestroni GMJ, Conti A, Reiter RJ (eds): Therapeutic potential of melatonin. Front Horm Res. Basel, Karger, 1996, vol 23, pp 36-42.
69. Mazzucchelli C, Pannacci M, Nonno R, Lucini V, Fraschini F, Stankov BM: The melatonin receptor in the human brain: Cloning experiments and distribution studies. Mol Brain Res 1996;39:117-126.
70. Menendez-Pelaez A, Reiter RJ: Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization. J Pineal Res 1993;15:59-69.
71. Acuña Castroviejo D, Reiter RJ, Menendez-Pelaez A, Pablos MI, Burgos A: Characterization of high-affinity melatonin binding sites in purified cell nuclei of liver. J Pineal Res 1994;16:100-112.
72. Becker-Andre M, Wiesenberg I, Scaeren-Wiemer N, Andre E, Missbach M, Saurat JH, Carlberg C: Pineal hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994;269:28531-28534.
73. Benitez-King G, Huerto-Delgadillo L, Anton-Tay F: Melatonin modifies calmodulin cell levels in MDCK and NIE-115 cell lines and inhibits phosphodiesterase activity in vitro. Brain Res 1991;557:289-292.
74. 2+/calmodulin-dependent kinase II activity by melatonin. Bio-chem Biophys Acta 1996;1290:191-196.
75. 3H melatonin to calmodulin. Life Sci 1993; 53:201-207.
76. Pozo D, Reiter RJ, Calvo JR, Guerrero JM: Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci 1994;55:PL445-PL460.
77. Reiter RJ, Melchiori D, Sewerynek E, Poeggeler B, Walden-Barlow LR, Chuang JI, Ortiz GG, Acuña-Cas-troviejo D: A review of the evidence supporting melatonin’s role as an antioxidant. J Pineal Res 1995; 18: 1-11.
78. Reiter RJ: Oxidative processes and antioxidative defense mechanism in the aging brain. FASEB J 1995;9: 526-533.
79. Blask DE: Melatonin in oncology; in Yu H, Reiter RJ (eds): Melatonin: Biosynthesis, Physiological Effects and Clinical Application. Boca Raton, CRC Press, 1993, pp 448-464.
80. Stankov B, Scaglione F, Lucini V, Fraschini F: Specific binding in vitro and in vivo effects of melatonin on melanoma B16 and its metastatic growth. Proc 16th Int Congr Che-mother June, Jerusalem, 1989, pp 893,1-893,3.
81. Shellard SA, Whealan RD, Hill BT: Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumor cell lines in vitro. Br J Cancer 1989;60:288-290.
82. L’Hermite-Balerieaux M, de Lau-noit Y: Is melatonin really an in vitro inhibitor of human breast cancer cell proliferation? In Vitro Cell Dev Biol 1992;28A:583-584.
83. Bartsch H, Bartsch C, Simon WE, Flehmig B, Ebels I, Lippert TH: Antitumor activity of the pineal gland: Effect of unidentified substances versus the effect of melatonin. Oncology 1992;49:27-30.
84. Bartsch C, Bartsch H, Lippert TH: The pineal gland and cancer: Facts, hypotheses and perspectives. Cancer J 1992;5:194-199.
85. Crespo D, Fernandez-Viadero C, Verduga R, Ovejero V, Cos S: Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res 1994;16:215-222.
86. Hill SM, Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988;48:6121-6126.
87. Cos S, Sanchez-Barcelo EJ: Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett 1994;85: 105-109.
88. Cos S, Sanchez-Barcelo EJ: Melatonin inhibition of MCF-7 human breast cancer cells growth: Influence of cell proliferation rate. Cancer Lett 1995;93:207-212.
89. Cos S, Blask DE: Effects of the pineal hormone melatonin on the anchorage independent growth of human breast cancer cells (MCF-7) in a clonogenic culture system. Cancer Lett 1990;50:115-119.
90. Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Res 1992;64:249-256.
91. Cos S, Blask DE: Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res 1994;17:25-32.
92. Blask DE, Hill SM: Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neural Transm suppl 1986;21: 433-449.
93. Cos S, Recio J, Sanchez-Barcelo EJ: Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci 1996;58:811-816.
94. Lemus-Wilson A, Kelly PA, Blask DE: Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer 1995;72:1435-1440.
95. Morgan PJ, Barrett P, Howell HE, Helliwell R: Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem Int 1994;24:101-146.
96. Gilad E, Laudon M, Matzkin H, Pick E, Sofer M, Braf Z, Zisapel N: Functional melatonin receptors in human prostate epithelial cells. Endocrinology 1996;137:1412-1417.
97. Fauteck JD, Lerchl A, Bergmann M, Moller M, Fraschini F, Wittkowski W, Stankov B: The adult human cerebellum is a target of the neuroendocrine system involved in the circadian timing. Neurosci Lett 1994; 179:60-64.
98. Yie SM, Niles LP, Younglai EV: Melatonin receptors on human granulosa cell membranes. J Clin Endocrinol Metab 1995;80:1747-1749.
99. Ying SW, Niles LP, Crocker C: Human malignant melanoma cells express high-affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 1993;246:89-96.
100. 125I]Io-domelatonin binding in normal and neoplastic tissues; in Fraschini F, Reiter RJ, Stankov B (eds): Role of Melatonin and Pineal Peptides in Neuroimmunomodulation. NATO ASI Series, Life Sci. New York, Plenum, 1991, vol 204, pp 117-125.
101. Molis TM, Walters SM, Hill SM: Melatonin modulation of estrogen receptor expression in MCF-7 human breast cancer cells. Int J Oncol 1993;3:687-694.
102. Hull KM, Maher TJ, Jorgenson JL: Melatonin increases cfos mRNA in MCF-7 human breast cancer cells (abstract 773.5). Soc Neurosci, 1993, vol 19, pp 1896.
103. Danforth DN Jr, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME: Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 1985;3: 941-948.
104. Cos S, Blask DE, Lemus-Wilson A, Hill AB: Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture. J Pineal Res 1991;10:36-42.
105. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB: Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 1986;46:4613-4619.
106. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS: Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance. Mol Endocrinol 1988;2:543-555.
107. Dickson RB, Huff KK, Spencer EM, Lippman ME: Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986;118: 138-142.
108. 2+ and calmodulin are involved in the processes conferring stability to DNA in proliferating neoplastic cells. Int J Cancer 1986;37:891-896.
109. Hagan RM, Oakley NR: Melatonin comes of age? Trends Pharmacol Sci 1995;16:81-83.
110. Benitez-King G, Huerto-Delgadil-lo L, Anton-Tay F: Melatonin effects on the cytoskeletal organisation of MDCK and neuroblastoma N1E-115 cells. J Pineal Res 1990; 9:209-220.
111. Pieri C, Marra M, Moroni F, Rec-chioni R, Marcheselli F: Melatonin: A peroxyl radical scavenger more effective than vitamin E. Life Sci 1994;55:PL271-PL276.
112. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ: Melatonin: A potent endogenous hydroxyl radical scavenger. Endocr J 1993;1:57-60.
113. Blask DE, Wilson ST: Melatonin action on human breast cancer cells: Involvement of glutathione metabolism and redox environment; in Fraschini F, Reiter RJ, Stankov B (eds): The Pineal Gland and Its Hormones: Fundamental and Clinical Perspectives. NATO ASI Series, Life Sci. New York, Plenum, 1995, vol 204, pp 209-217.
114. Vijayalaxmi, Reiter RJ, Meltz ML: Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mu-tat Res 1995;346:23-31.
115. Blask DE, Hill SM, Orstead KM, Massa JS: Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7, 12-dimethylbenzan-thracene (DMBA)-induced mammary tumorigenesis. J Neural Transm 1986;67:125-138.
116. Cohen LA, Choi K, Wang CX: Influence of dietary fat, caloric restriction and voluntary exercise on N-nitrosomethylurea-induced mammary tumorigenesis in rats. Cancer Res 1988;48:426-428.
117. Birt DF, Kris ES, Choe M, Pelling JC: Dietary energy and fat effect on tumor promotion. Cancer Res 1992;52(suppl):2035s-2039s.
118. Vaughan MK, Vaughan GM: Met abolic and thyroidal consequences of melatonin administration in mammals; in YU HS, Reiter RJ (eds): Melatonin: Biosynthesis, Physiological Effects, and Clinical Implications, Boca Raton, CRC, 1993, pp 311-347.
119. Blask DE, Sauer LA, Dauchy RT: Melatonin suppression of tumor growth in vivo: A novel mechanism involving inhibition of fatty acid uptake and metabolism; in Maestroni GJ, Conti A, Reiter RJ (eds): Therapeutic Potential of Melatonin. Front Horm Res. Basel, Karger, 1997, vol 23, pp 107-114.
120. Lissoni P, Barni S, Tancini G, Crispino S, Paolorossi F, Lucini V, Mariani M, Cattaneo G, Esposti D, Esposti G: Clinical study of melatonin in untreatable advanced patients. Tumori 1987;73:475-480.
121. Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F: Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 1989;25:789-795.
122. Lissoni P, Barni S, Cattaneo G, Tancini G, Esposti G, Esposti D, Fraschini F: Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology 1991;48:448-450.
123. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G, Conti A, Maestroni GJ: Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first line chemotherapy containing cisplatin. Oncology 1992;49:336-339.
124. DiBella L, Rossi MT, Scalera G: Perspectives in pineal functions. Prog Brain Res 1979;52:475-478.
125. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S: Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993;79:401-404.
126. Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni GJ: A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994;73:699-701.
127. Aldeghi R, Lissoni P, Barni S, Ar-dizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A, Maes-troni GJ: Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994;30:167-170.
128. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G: Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-856.
129. Neri B, Fiorelli C, Moroni F, Nici-ta G, Paoletti MC, Ponchietti R, Raugel A, Santoni G, Trippitelli A, Grechi G: Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer 1994;73:3015-3019.
130. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, Frigerio F: A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994;80: 464-467.
131. Lissoni P, Ardizzoia A, Barni S, Brivio F, Tisi E, Rovelli F, Tancini G, Maestroni GJ, Fumagalli L: Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin: A progress report of 200 patients with advanced solid neoplasms. Oncol Rep 1995;2:1063-1068.